NCT02924155CompletedPhase 1
A Randomized, Double-blind, Placebo-controlled, Single Day/Multiple Day Dosing, Phase I Clinical Trial to Investigate the Systemic Exposure, Safety and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Korean Male Subjects
Samjin Pharmaceutical Co., Ltd.1 site in 1 country12 target enrollmentStarted: September 5, 2016Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Incidence of Treatment Emergent Adverse Event(TEAE)
Study Overview
Brief Summary
This is a phase1, single center, double-blind, placebo control, randomized study and consisted of single dosing(period 1) and multiple dosing(period 2).
In this clinical trial, safety and local tolerability are evaluated for 7 days after single dosing of the investigational product. If multiple dosing is judged to be acceptable as a result of single dosing evaluation (safety and local tolerability evaluation including ophthalmic examination), multiple dosing starts from Day 8(7 days after the single dosing) for 14 days. Safety and local tolerability, including ophthalmic symptom assessment, should be evaluated during the multiple dosing period.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 20 Years to 50 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subject who voluntarily agrees to participate in this study and has given a written informed consent, after fully understanding the detailed explanation of this study
- •20 years to 50 years (Healthy male Korean)
Exclusion Criteria
- •Subject with a disease history of any clinically significant condition as below.
- •Liver, Kidney, nervous system, immune system, respiratory system, endocrine system, tumor, cardiovascular disease or mental illness (mood disorder or obsessive-compulsive disorder etc.) etc.
- •Subject with a history of clinically significant hypersensitivity or hypersensitivity reactions to drugs (aspirin, antibiotics, etc.)
- •Subject with a disease history of any ophthalmic condition as below
- •History of or suspected symptoms or signs of vision problems, including keratitis, uveitis, retinitis, dry eye syndrome, and strabismus.
- •Corrected eyesight measured at screening is 20/40 or less
- •Those who have previously had ophthalmic surgery. (Exceptional case: in the case of having ophthalmic laser surgery before 6 months from the screening)
- •Those who have experienced side effects after wearing contact lenses, those who have worn contact lenses within the last month, or those who cannot ban wearing contact lens during the clinical trial
- •Abnormal findings in other ophthalmic examinations
- •Subject with a history of drug abuse or who is positive for drugs of abuse in urine tests at screening
- •Subject who received any drugs such as
- •Prescription drug or herbal medicine within 14 days prior to the first administration of the investigational products
- •Over the counter (OTC) or vitamin within 7 days prior to the first administration of the investigational products
- •Subject who received other investigational products within 90 days prior to the first administration of the investigational products
- •Subject who have donated whole blood within 60 days prior to the first administration of the investigational products, or donated component blood or have received blood transfusion within 30 days prior to the first administration of the investigational products
- •Subject who continuously drink alcohol (more than 21 units/week, 1 unit = 10 g of pure alcohol) or cannot abstain from alcohol during the study period
- •Subject who smoked more than 10 cigarettes a day on average in the last 90 days, and who cannot quit smoking during hospitalization
- •Man of reproductive potential not willing to use contraceptive measures during the study period
- •Subject not eligible for study participation in the opinion of the investigator
Arms & Interventions
SJP002
Experimental
9 subjects received single dose of SJP002 and then received multiple dose of SJP002
Intervention: SJP002 (Drug)
Placebo
Placebo Comparator
3 subjects received single dose of placebo and then received multiple dose of placebo
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Incidence of Treatment Emergent Adverse Event(TEAE)
Time Frame: Day 1(administration) to approximately Day 37(Post study visit)
Safety/Tolerability Assessment
Secondary Outcomes
- Measure the Peak Plasma Concentration (Cmax) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Area Under the plasma concentration versus time Curve from the first observed to last(AUClast) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Area Under the plasma concentration versus time Curve from the first sampled data extrapolated to infinity(AUCinf) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Time to peak drug concentration(Tmax) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Half Life(t1/2) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Trough Drug Concentration at steady state(Cmin,ss) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
- Measure the Area Under the plasma concentration-time Curve over a dosing interval at steady state(AUCtau,ss) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
- Measure the Time to peak drug concentration at steady state(Tmax,ss) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
- Measure the Half Life at steady state(T1/2,ss) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
- Measure the Peak Plasma Concentration Accumulation Ratio (RA,Cmax) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Phase I Study of SB26 in Healthy VolunteersHealthy VolunteersNCT03630627Samsung Bioepis Co., Ltd.58
Completed
Phase 1
Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy VolunteersHealthy SubjectsNCT05201690Vigonvita Life Sciences36
Completed
Phase 1
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult ParticipantsNon-alcoholic SteatohepatitisNCT06716905Xiamen Amoytop Biotech Co., Ltd.72
Completed
Phase 1
A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult SubjectsHealthyNCT04976270Galapagos NV23
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese ParticipantsHealthy VolunteersNCT04138043GlaxoSmithKline9